Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quadrivalent influenza vaccine (MDCK cell)
- Development stage
- Unknown
- Lead developer
- Wuhan Institute of Biological Products
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The quadrivalent influenza vaccine (MDCK cell) is an inactivated split-virion vaccine developed by the Wuhan Institute of Biological Products (WIBP), a subsidiary of Sinopharm's China National Biotec Group (CNBG). Unlike traditional influenza vaccines produced in embryonated chicken eggs, this vaccine is manufactured using Madin-Darby Canine Kidney (MDCK) cell culture technology. This method avoids egg-adaptation mutations that can reduce vaccine effectiveness and allows for a more scalable and rapid production process. The vaccine is designed to provide protection against four distinct influenza virus strains: two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). It is currently in Phase 3 clinical trials for the prevention of influenza in individuals aged 3 years and older.
- Other names
- 四价流感病毒裂解疫苗（MDCK细胞）
02
Targets
HA (Hemagglutinin)HA-BCR (Influenza hemagglutinin-specific B-cell receptor)TCR (CD4+ T-cell receptor)
Beyond the preview
Go deeper on quadrivalent influenza vaccine (MDCK cell).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quadrivalent influenza vaccine (MDCK cell).